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Abstract
One out of ten patients with Philadelphia-negative myeloproliferative neoplasms
(MPN) develop a second cancer (SC): in such patients we aimed at assessing the sur-
vival impact of SC itself and of MPN-specific therapies. Data were therefore
extracted from an international nested case-control study, recruiting 798 patients
with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs)
were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1-6.9) deaths
for every 100 PYs. A “poor prognosis” SC (stomach, esophagus, liver, pancreas, lung,
ovary, head-and-neck or nervous system, osteosarcomas, multiple myeloma, aggres-
sive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the
cause of death in 65% of them (MR 11.0/100 PYs). In contrast, patients with a “non-
poor prognosis” SC (NPPSC) incurred a MR of 4.6/100 PYs: 31% of the deaths were
attributed to SC and 15% to MPN evolution. At multivariable analysis, death after SC
diagnosis was independently predicted (HR and 95% CI) by patient age greater than
70 years (2.68; 1.88-3.81), the SC prognostic group (2.57; 1.86-3.55), SC relapse
(1.53; 10.6-2.21), MPN evolution (2.72; 1.84-4.02), anemia at SC diagnosis (2.32;
1.49-3.59), exposure to hydroxyurea (1.89; 1.26-2.85) and to ruxolitinib (3.63;
1.97-6.71). Aspirin was protective for patients with a NPPSC (0.60; 0.38-0.95). In
conclusion, SC is a relevant cause of death competing with MPN evolution. Prospec-
tive data are awaited to confirm the role of cytoreductive and anti-platelet drugs in
modulating patient survival after the occurrence of a SC.
1 | INTRODUCTION
Philadelphia-negative myeloproliferative neoplasms (MPN) are chronic
bone marrow disorders associated with a variable prognosis depending
on the occurrence of vascular events and the transformation into mye-
lofibrosis, myelodysplasia or acute myeloid leukemia. In addition to
these incident events, recent studies consistently reported that MPN
patients are also prone to an increased risk of developing second can-
cers (SC).1-5 Blood and solid cancers occur in about 17% of patients
with MPN, often preceding the diagnosis of MPN: melanoma, prostate
cancer and non-MPN blood cancers have been diagnosed in excess as
compared with control population in North Europe registry studies.6
We recently published the results from a nested case–control
study with 647 MPN patients with SC and 1234 matched controls
(MPN patients without SC) recruited from European LeukemiaNet
(ELN) centers and reported that the exposure to cytoreductive drugs,
such as hydroxyurea and ruxolitinib, increases the occurrence of non-
melanoma skin cancers.7
In the present study, we re-examined this large database with the
following two purposes: (a) to evaluate the prognosis of MPN patients
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with SC and (b) to establish whether cytoreductive and antiplatelet
therapies have any impact on the survival of such patients.
2 | METHODS
Details of this multicenter international nested case-control study
(MPN-K Study, ClinicalTrials.gov: NCT03745378) have been reported
elsewhere.7 Each center reported patients diagnosed with MPN
(according to PVSG, 2008 and 2016 WHO) in the years 2000 to 2016
and concurrently or subsequently reporting a solid or blood cancer.
Index date was the date of SC diagnosis. The present paper reports
the data of all the 798 patients with a SC diagnosis enrolled in the
MPN-K study that included 647 patients with and 151 patients with-
out matched controls.
Patients were grouped into two prognostic classes based on the
5-year relative survival from cancer diagnosis.8 The “poor progno-
sis” SC group (PPSC) included cancers in the stomach, esophagus,
liver, pancreas, lung, ovary, head-and-neck, nervous system, osteo-
sarcomas, multiple myeloma, aggressive lymphoma, acute leukemia;
the “non-poor prognosis” SC group (NPPSC) included melanoma,
non-melanoma skin cancer, kaposi sarcoma, chronic lymphocytic
leukemia, indolent non-Hodgkinʼs lymphoma and cancers in breast,
colorectal, prostate/urinary tract, kidney, duodenal, endocrine and
neuroendocrine system.
The study requested centers to provide the date and cause of
death as well as treatments for MPN since MPN diagnosis, treatments
for SC, MPN evolution and SC relapse during follow-up.
TABLE 1 Characteristics of MPN patients with a second
cancer (SC)
N (%) Total = 798
Characteristics at MPN diagnosis
MPN diagnosis
PV 275 (34.5%)
ET 396 (49.6%)
MF 127 (15.9%)
Age, mean ± SD 63.4 ± 12.1
Male gender 419 (52.5%)
JAK2 V617 mutation 603 (75.6%)
CV risk factors (smoke, hypertension,
dislipidemia, diabetes, alcohol, obesity)
569 (71.3%)
Characteristics at SC occurrence
Age, mean ± SD 68.9 ± 11.3
HB (g/dl), median (Q1, Q3) 13.2 (11.9, 14.5)
WBC (109/l), median (Q1, Q3) 7.6 (5.9, 10.1)
HCT (%), median (Q1, Q3) 41.0 (36.3, 44.7)
PLT (109/L), median (Q1, Q3) 409.0 (282.0, 556.0)
Splenomegaly (n = 21 missing) 164 (20.6%)
Prognostic groupsa
Non-poor prognosis SC (NPPSC) 587 (73.6%)
Melanoma 36 (4.5%)
Non-melanoma skin cancer 164 (20.6%)
Breast cancer 101 (12.7%)
Colorectal cancer 69 (8.6%)
Prostate/urinary tract cancer 153 (19.2%)
Kidney cancer 7 (0.9%)
Endocrine cancer 13 (1.6%)
Kaposi sarcoma 1 (0.1%)
Duodenal neuroendocrine tumor 1 (0.1%)
CLL 18 (2.3%)
Indolent NHL 24 (3.0%)
Poor prognosis SC (PPSC) 209 (26.2%)
Ovary/uterus cancer 29 (3.6%)
Upper gastrointestinal tract cancer 27 (3.4%)
Liver/pancreas cancer 18 (2.3%)
Respiratory tract trachea bronchus lung 69 (8.6%)
Head & neck cancer 20 (2.5%)
Cerebral cancer 3 (0.4%)
Osteosarcoma 1 (0.1%)
Muscle sarcoma 1 (0.1%)
Liposarcoma 2 (0.3%)
MM/WD 19 (2.4%)
Aggressive NHL 10 (1.3%)
T-cell lymphomas 8 (1.0%)
ALL/Burkitt lymphoma 2 (0.3%)
(Continues)
TABLE 1 (Continued)
N (%) Total = 798
Treatments before/at SC occurrence
Hydroxyurea 552 (69.2%)
Ruxolitinib 33 (4.1%)
Interferon 29 (3.6%)
Pipobroman 30 (3.8%)
Busulfanb 20 (2.5%)
Aspirin 607 (76.1%)
Major events after SC occurrence
Thrombosis 86 (10.8%)
Arterial 44 (5.5%)
Venous/Splanchnic 42 (5.3%)
Major bleeding 39 (4.9%)
MPN evolution 63 (7.9%)
SC relapse 108 (13.6%)
Death 178 (22.3%)
Note: For two patients, SC type was not available.
aBased on classification of Zheng et al.8
bFive patients were treated with both hydroxyurea and busulfan.
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2.1 | Statistical methods
Descriptive statistics were used to summarize the characteristics of
MPN patients with SC. Categorical variables were presented as a
number and percentage, while continuous variables were presented
as a mean and SD (SD).
Survival after SC diagnosis was estimated by the Kaplan-Meier
method and was compared in PPSC and NPPSC using the log-rank
test. Age and gender-adjusted survival curves were estimated by a
Cox proportional-hazard model.
Cumulative incidence function (CIF) of cause-specific mortality
adjusted for age and gender was estimated with the competing-risk
method and stratified by prognostic group. A multivariable Cox
proportional-hazard model was fitted to estimate the Hazard Ratio
(HR) of death, as well as the corresponding 95% confidence interval
(CI). This was associated with the occurrence of thrombosis before/
at diagnosis of MPN and during follow-up in the whole cohort and
stratified by prognostic group. Adjustments were made for patient
characteristics at MPN diagnosis (age, sex, typology of MPN, cardio-
vascular risk factors, JAK2V617F mutation) but also for MPN evolu-
tion (myelofibrosis, acute leukemia, myelodysplasia), thrombosis and
treatments during follow-up. Adjustments were further made for
patient characteristic at SC diagnosis (hemoglobin levels (HB), plate-
let count (PLT), leukocyte count (WBC), splenomegaly), for SC
relapse during the follow-up and for vascular events preceding
(thrombosis) or following (bleeding or thrombosis) SC diagnosis. Cau-
ses of death were considered as multiple “competing” outcomes, and
cause-specific CIFs were accordingly estimated by the competing
risk method.
For all hypotheses tested, two-tailed P-values less than 0.05 were
considered to be significant.
Analyses were performed using STATA software, release 13
(StataCorp LP, College Station TX, USA).
3 | RESULTS
3.1 | Study population
The study included 798 MPN patients with a SC (Table 1). Neoplasms
occurred most frequently in the prostate, the breast, the skin (basal cell
carcinoma) and the lymphoid tissue. The PPSC were reported in
209 cases (26%): 68 cancers occurred in the lung and 47 in the stom-
ach, esophagus or head&neck, while 39 SC were aggressive lympho-
proliferative disorders. Chemotherapy was prescribed for the treatment
of SC in 78 (9.8%) of the patients.
3.2 | Survival analysis
Overall 2995 person-years (PYs) were accumulated and 178 deaths
occurred (median: 3.0, interquartile range 1.0-3.4), with a mortality
rate (MR) of 5.9 deaths for every 100 PYs (95% CI: 5.1-6.9).
During the follow-up, 108 (13.5%) relapsed their SC and the
major cause of death was SC itself in 78 (43.8%). The MPN evolution
caused 21 deaths (11.8%), infection 23 deaths (12.9%) and
F IGURE 1 Survival curves adjusted for age and gender stratified
by prognostic groups (NPPSC, non-poor prognosis SC, PPSC, poor-
prognosis SC) [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Multivariable Cox proportional-hazard model for
predictors of all-cause mortality
HR (95% CI) P
Prognostic group
NPPSC 1.00 (Ref.)
PPSC 2.57 (1.86-3.55) .000*
Age at SC > 70 2.68 (1.88-3.81) .000*
Male gender 1.14 (0.83-1.57) .425
MPN diagnosis
PV/ET 1.00 (Ref.)
MF 1.13 (0.74-1.73) .568
CV risk factors 0.84 (0.59-1.19) .321
JAK2 mutation 0.99 (0.68-1.45) .966
PLT at SC < 150 × 109/L 1.44 (0.89-2.33) .134
HB at SC < 10 g/dL 2.32 (1.49-3.59) .000*
WBC at SC < 10 × 109/L 0.76 (0.54-1.05) .098
Splenomegaly at SC 1.22 (0.84-1.76) .290
Thrombosis before SC 0.92 (0.53-1.59) .764
Thrombosis after SC 0.95 (0.59-1.53) .838
Bleeding after SC 0.66 (0.34-1.30) .230
Hydroxyurea 1.89 (1.26-2.85) .002*
Ruxolitinib 3.63 (1.97-6.71) .000*
Aspirin 0.77 (0.53-1.11) .160
Relapse of SC 1.53 (1.06-2.21) .023*
MPN evolution 2.72 (1.84-4.02) .000*
Abbreviations: HB, hemoglobin levels; NPPSC, non-poor prognosis SC;
PLT, platelet count; PPSC, poor-prognosis SC; WBC, leukocyte count.
*Significant associations with mortality (p-values < 0.05).
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cardiovascular disorders 11 deaths (6.2%). Other causes of death were
reported for 17 patients (9.6%) and the cause of death was not
reported for 28 patients (15.7%).
The MR was much poorer in PPSC (11.0 vs 4.6 deaths per 100 PYs;
P < .01) with only 36% (vs 64%) alive at 10 years from diagnosis
(Figure 1). In particular, respiratory cancers incurred a dismal MR of
23.9/100 PYs, corresponding to 44% 5-year and 17%10-year survival.
During the follow-up from SC diagnosis 7.9% of the patients experi-
enced an evolution of their MPN into myelofibrosis, myelodysplasia or
acutemyeloid leukemia. And,MRwas significantly poorer inMF patients
(10.4/100 PYs vs 5.7 PV and 4.9 ET; P = .004) and the prognosis of
patientswith NPPSCwas effected byMPN evolution (Figure S1).
Fifteen years after SC occurrence, the CIF of SC-related mortality
was 16%, while by MPN evolution was 6% and by other causes 19%.
In the subgroup with PPSC, however, the cumulative mortality inci-
dence caused by SC was 32% vs 1% by MPN vs 17% by other causes.
Among the 33 patients who had been treated with ruxolitinib,
16 died during follow-up: SC was the cause of death for eight of them
(50%), infection for three patients (18.8%) and cardiovascular events
for two of them (12.5%), while none died of MPN evolution. Other
causes of death were reported for one patient (6.3%) and no cause of
death was reported for two (12.5%).
3.3 | Multivariable analysis
Multivariable analysis of survival after SC diagnosis (Table 2) confirmed
the predictive power of the type of SC (ie, PPSC) and its clinical
behavior (ie, relapse), as well as clinical evolution of MPN and anemia.
However, the analysis also pointed out that exposure to hydroxyurea
or Ruxolitinib since MPN diagnosis was independently associated with
a poorer outcome after SC diagnosis. The HR reported for hydroxyurea
(2.69; 1.25-5.80) and ruxolitinib (9.19; 3.03-27.56) in the PPSC group
were statistically significant also in the subgroup of patients with
NPPSC (Figure 2).
In the subgroup of patients with NPPSC aspirin was indepen-
dently associated with a 50% reduction of risk of death (HR 0.50;
0.31-0.79; = .003).
4 | DISCUSSION
SCs are a major issue occuring in over 8% of overall cancer patients:
more than half of whom die of their second primary malignancy.9 The
risk of second primary malignancies is particularly high in patients with
primary lymphoid neoplasms,9 but is also significantly increased in
myeloid neoplasms.5 In particular, cancers in the upper gastrointesti-
nal tract, nose, lung, kidney, skin, endocrine gland and nervous system
are significantly increased in MPN patients as compared with the gen-
eral population.5 The genetic basis of multiple primary cancers is not
well-known, however, the JAK2V617F mutation was associated with
both solid and lymphoid neoplasms, and the rs2736100_C SNP of
TERT has been proved to increase the risk of solid cancers in MPN
patients.10-15 In MPN patients, cyotoreductive drugs have been impli-
cated in the development of non-melanoma skin cancers, but not of
other cancers.7
F IGURE 2 Multivariable Cox proportional-hazard model for predictors of all-cause mortality stratified by prognostic group (HB, hemoglobin
levels; NPPSC, non-poor prognosis SC; PLT, platelet count; PPSC, poor-prognosis SC; WBC, leukocyte count) [Color figure can be viewed at
wileyonlinelibrary.com]
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This study reported the survival outcomes of 798 cases of SC
occuring a median of 9 years after MPN diagnosis, and retrieved from
an international multi-country study. Survival was shown to be dismal,
as only in the 26% of the patients who had a PPSC (stomach, esopha-
gus, liver, pancreas, lung, ovary, head-and-neck or nervous system,
osteo-sarcomas, multiple myeloma, aggressive lymphomas and acute
leukemias). Five-year survival of lung cancer patients, however, was
not inferior to the rates reported for non-MPN patients.16 The
reported survival of patients incurring a PPSC was significantly
reduced by elderly status (ie, age over 70 years), thrombocythopenia,
leukocytosis, but also by exposure to cytoreductive drugs such as
hydroxyurea (HR 2.69) or ruxolitinib (HR 9.14).
In patients with NPPSC cytoreductive drugs were independent
predictors of survival after SC diagnosis, despite adjustment for initial
MPN diagnosis, MPN evolution during the follow-up as well as for
anemia, thrombocytopenia and leukocytosis at SC diagnosis.
The association of exposure to hydroxyurea and ruxolitinib with
patient survival after SC diagnosis, regardless of MPN status and of
cytopenias at SC diagnosis, was clinically relevant. We suppose that
actively treated patients may have received a less aggressive treat-
ment for their SC or poorly tolerated SC-targeted chemotherapy.
However, we investigated also further hypotheses for ruxolitinib,
since the association with survival was impressive. Ruxolitinib has
been tested in patients with colorectal cancer,17 multiple myeloma,18
breast cancer,19 lung cancer,20,21 and other neoplasms in small phase
1-2 studies. They were often early interrupted and did not report any
detrimental or beneficial effect of the drug onto patient survival.
However, co-harboring of JAK2 and PDL1/PDL2 genes by the same
9p24.1 region allowed us to hypothesize some interaction of JAK2
inhibition with PDL1 expression and cancer immunosurveillance.
However, in breast cancers, a high JAK2 expression was associated
with a higher degree of tumor infiltration by lymphocytes and a signif-
icantly lower risk of recurrence.22 However, 9p24.1 amplifications
reported in lymphomas, triple-negative breast cancers and lung can-
cers resulted in both increased JAK2 and PDL1 expression.23 Based on
these premises, one would expect that JAK2 inhibition might also
reduce PDL1 expression, which has been proved in triple-negative
breast cancer with 9p24.1 amplification.24 However, inhibition of
STAT3 pathway has been proven both to reduce the tumor infiltrating
lymphocytes and response to checkpoint inhibitors,25 and to interfere
with the lymphocyte tumor-inhibitory Th1 pathway.22 Since
immunosurveillance is a major driver of survival in solid cancers,26 we
hypothesize that exposure to ruxolitinib in patients with SC might
have favored cancer progression in a subgroup of SC patients. We
therefore suggest caution in the use of checkpoint inhibitors concur-
rently with ruxolitinib in MPN patients developing SC. However, fur-
ther studies are warranted to explore the biologic and clinical reasons
for the interaction of ruxolitinib with SC prognosis documented by
the present study.
Arterial thrombosis may herald SC in MPN patients,27 but in our
analysis had no impact on the prognosis of SC either before and after
diagnosis of SC. However, aspirin was a strongly protective agent in
the subset of NPPSC, where cause of death was equally distributed
between MPN evolution, SC and other causes. However, a modest
reduction of cancer-specific mortality in aspirin users has been widely
demonstrated especially for colon cancer but also for breast cancer,
hepatocellular carcinoma and other malignant neoplasms.28,29
Note, MPN was the principal cause of death in 11.8% of patients
incurring NPPSC, moreover, infections were a relevant cause of death,
which may be partially related to MPN itself. Furthermore, NPPSC do
not lead to a dismal survival, therefore, MPN patients with a NPPSC
should be cared for carefully with regard to their MPN, and vascular
events diligently prevented.
The limited number of patients treated with ruxolitinib in the pre-
sent retrospective study may hamper the clinical validity of the very
high HR reported for the drug. Therefore, larger controlled studies are
awaited in the next years. Also, future prospective studies targeting
germinal and acquired genetic factors predisposing individuals to
MPN and to multiple primary cancers are awaited, in order to person-
alize MPN-directed therapies. Moreover, the impact of previous
and/or ongoing exposure to cytoreductive and antiplatelet drugs in
patients harboring a SC needs to be confirmed by prospective studies.
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